Emerging drugs for the treatment of metastatic renal cancer

Expert Opinion on Emerging Drugs

Volumn 12, Issue 4, 2007, Pages 605-618

  Samlowski, Wolfram E ^a   Vogelzang, Nicholas J ^a  

^a NEVADA CANCER INSTITUTE   (United States)

Author keywords

Kidney cancer; Monoclonal antibody; mTOR; Signaling inhibitor; Targeted therapy; Tyrosine kinase inhibitor; Vascular endothelial growth factor; VEGFR

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA INTERFERON; AP 23573; AXITINIB; BAY 73 4506; BEVACIZUMAB; BIBF 1120; BMS 582664; DENDRITIC CELL VACCINE; DIPHENHYDRAMINE; EVEROLIMUS; GEFITINIB; IMATINIB; INTERLEUKIN 2; KRN 951; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PAZOPANIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SORAFENIB; SU 14813; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; XL 184; XL 647; XL 999;

ADJUVANT THERAPY; ANEMIA; ARTHRALGIA; ASTHENIA; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COGNITION; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HAIR COLOR; HAIR DISCOLORATION; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IC 50; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE PAIN; KIDNEY CANCER; KIDNEY PERFUSION; LIVER FUNCTION TEST; LUNG EDEMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MANIA; MEDICAL RESEARCH; MELANOMA; METASTASIS; MONOTHERAPY; MOUTH PAIN; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PNEUMONIA; PROTEINURIA; PRURITUS; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VOICE CHANGE; VOMITING; VON HIPPEL LINDAU DISEASE; WEIGHT GAIN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36549057831     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.4.605     Document Type: Review

References (103)

1. LINEHAN WM, BATES SE, YANG JC: Cancer of the kidney. In: Cancer: Principles and Practice of Oncology. (Volume 7). DeVita VT, Hellman S, Rosenberg SA (Eds), Lippincott, Williams & Wilkins, Philadelphia, USA (2006):1139-1167.
2. BUKOWSKI RM: Immunotherapy in renal cell carcinoma. Oncology (1999) 13(6):801-810. • Review of IL-2 and interferon therapy.
3. JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. Cancer J. Clin. (2007) 57:43-66.
4. MOORE LE, WILSON RT, CAMPLEMAN SL: Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest. (2005) 23(3):240-255.
5. KIM HL, BELLDEGRUN AS, FREITAS DG et al.: Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J. Urol. (2003) 170(5):1742-1746.
6. COHEN HT, MCGOVERN FJ: Renal-cell carcinoma. N. Engl. J. Med. (2005) 353(23):2477-2490.
7. MOTZER RJ, BANDER NH, NANUS DM: Renal-cell carcinoma. N. Engl. J. Med. (1996) 335(12):865-875.
8. LEONARD WJ: Type I cytokines and interferons and their receptors. In: Fundamental Immunology. Paul WE (Ed.), Lippincott, Williams & Wilkins, Philadelphia, USA (2003):701-748.
9. WEISS A: T lymphocyte activation. In: Fundamental Immunology. Paul WE (Ed.), Raven Press, NY, USA (1993):467-504.
10. LOTZE MT, GRIMM EA, MAZUMDER A, STRAUSSER JL, ROSENBERG SA: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. (1981) 41:4420-4425.
11. RAYNER AA, GRIMM EA, LOTZE MT, WILSON DJ, ROSENBERG SA: Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J. Natl. Cancer Inst. (1985) 75:67-75.
12. HANK JA, KOHLER PC, WEIL-HILLMAN G et al.: In vivo induction of the lymphokine-activated killer phenomenon: IL-2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin-2. Cancer Res. (1988) 48:1965-1971.
13. PAPA MZ, MULÊ JJ, ROSENBERG SA: Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res. (1986) 46:4973-4978.
14. LAFRENIERE R, ROSENBERG SA: Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. (1985) 45:3735-3741.
15. ROSENBERG SA, YANG JC, TOPALIAN SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 271:907-913.
16. FISHER RI, ROSENBERG SA, SZNOL M, PARKINSON DR, FYFE G: High-dose aldesleukin in renal cell carcinoma: long term survival update. Cancer J. Sci. Am. (1997) 3:S70-S72. •• A benchmark study of IL-2 treatment.
17. YANG JC, SHERRY RM, STEINBERG SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21(16):3127-3132.
18. SIEGEL JP, PURI RK: Interleukin-2 toxicity. J. Clin. Oncol. (1991) 9:694-704.
19. ROSENSTEIN M, ETTINGHAUSEN SE, ROSENBERG SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immunol. (1986) 137:1735-1742.
20. SAMLOWSKI WE: Nitric oxide as a mediator of interleukin-2 induced cardiovascular toxicity and antitumor activity. In: Nitric Oxide and Inflammation. Salvemini D, Billiar TR, Vodovotz Y (Eds), Birkhäuser Publishing Ltd, Basel, Switzerland (2001):249-272.
21. MAHER ER, WEBSTER AR, RICHARDS FM et al.: Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J. Med. Genet. (1996) 33(4):328-332.
22. SEIZINGER BR, ROULEAU GA, OZELIUS LJ et al.: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature (1988) 332(6161):268-269.
23. LATIF F, TORY K, GNARRA J et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 260(5112):1317-1320.
24. HERMAN JG, LATIF F, WENG Y et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA (1994) 91(21):9700-9704.
25. DUAN DR, HUMPHREY JS, CHEN DY et al.: Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl. Acad. Sci. USA (1995) 92(14):6459-6463.
26. MAXWELL PH, WIESENER MS, CHANG GW et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 399(6733):271-275.
27. COCKMAN ME, MASSON N, MOLE DR et al.: Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. (2000) 275(33):25733-25741.
28. GEORGE DJ, KAELIN WG Jr: The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med. (2003) 349(5):419-421.
29. PANTUCK AJ, ZENG G, BELLDEGRUN AS, FIGLIN RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin. Cancer Res. (2003) 9(13):4641-4652. • Rationale for development of VEGF pathway-inhibiting drugs.
30. DANCEY JE: Therapeutic targets: MTOR and related pathways. Cancer Biol. Ther. (2006) 5(9):1065-1073.
31. SCHEID MP, MARIGNANI PA, WOODGETT JR: Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol. Cell Biol. (2002) 22(17):6247-6260.
32. PANTUCK AJ, SELIGSON DB, KLATTE T et al.: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 109(11):2257-2267.
33. WANG X, FLYNN A, WASKIEWICZ AJ et al.: The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J. Biol. Chem. (1998) 273(16):9373-9377.
34. THOMAS GV, TRAN C, MELLINGHOFF IK et al.: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. (2006) 12(1):122-127.
35. GAO N, FLYNN DC, ZHANG Z et al.: G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol. (2004) 287(2):C281-C291.
36. VAN DUYNE GD, STANDAERT RF, KARPLUS PA, SCHREIBER SL, CLARDY J: Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J. Mol. Biol. (1993) 229(1):105-124.
37. ROBB VA, KARBOWNICZEK M, KLEIN-SZANTO AJ, HENSKE EP: Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. (2007) 177(1):346-352.
38. XU G, ZHANG W, BERTRAM P, ZHENG XF, MCLEOD H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int. J. Oncol. (2004) 24(4):893-900.
39. ROSS JS, QIAN J, SHEEHAN C, JONES D, JENNINGS T: Elevated phosphorylated mammalian target of rapamycin (p-mtor) expression in human neoplasms. Proc. ASCO (2007) 25:S582 (Abstract).
40. HERNANDO E, CHARYTONOWICZ E, DUDAS ME et al.: The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med. (2007) 13(6):748-753.
41. WILHELM SM, CARTER C, TANG L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. (2004) 64(19):7099-7109.
42. KARASARIDES M, CHILOECHES A, HAYWARD R et al.: B-RAF is a therapeutic target in melanoma. Oncogene (2004) 23(37):6292-6298.
43. EISEN T, AHMAD T, FLAHERTY KT et al.: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer (2006) 95(5):581-586.
44. RATAIN MJ, EISEN T, STADLER WM et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(16):2505-2512.
45. ESCUDIER B, EISEN T, STADLER WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):125-134. •• Randomized Phase III trial of sorafenib that led to FDA approval.
46. AMATO RJ, HARRIS P, DALTON M et al.: A Phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). Proc. ASCO (2007) 25:S241.
47. SUN L, LIANG C, SHIRAZIAN S et al.: Discovery of 5-[5-fluoro-2-oxo-1, 2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H- pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. (2003) 46(7):1116-1119.
48. BRITTEN CD, KABBINAVAR F, RANDOLPH HECHT J et al.: A Phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol. (2007).
49. MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295(21):2516-2524.
50. MOTZER RJ, MICHAELSON MD, REDMAN BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(1):16-24.
51. MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):115-124. •• Randomized Phase III trial of sunitinib that led to FDA approval.
52. ATKINS MB, HIDALGO M, STADLER WM et al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. (2004) 22(5):909-918.
53. MOTZER RJ, HUDES GR, CURTI BD et al.: Phase I/II trial of temsirolimus combined with interferon CC for advanced renal cell carcinoma. J. Clin. Oncol. (2007) 25(25):3958-3964.
54. HUDES G, CARDUCCI M, TOMCZAK P et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. (2007) 356(22):2271-2281. •• Randomized Phase III trial of temsirolimus that led to FDA approval.
55. YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349(5):427-434.
56. ESCUDIER B, KORALEWSKI P, PLUZANSKA A et al.: A randomized, controlled, double-blind Phase III study (AVOREN) of bevacizumab/interferon- α2a vs placebo/interferon-α2a as first line therapy in metastatic renal cell carcinoma. Proc. ASCO 25:S2 (Abstract). • Promising Phase III study of avastin/bevacizumab.
57. MOTZER RJ, BOLGER GB, BOSTON B et al.: Kidney cancer. Clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. (2006) 4(10):1072-1081.
58. CHOUEIRI TK, GARCIA JA, ELSON P et al.: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 110(3):543-550.
59. PEIFER C, KRASOWSKI A, HAMMERLE N et al.: Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor. J. Med. Chem. (2006) 49(25):7549-7553.
60. GEORGE DJ: Phase II studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin. Cancer Res. (2007) 13(2 Part 2):S753-S757.
61. RINIBI, WILDING GT, HUDES G et al.: Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. Proc. ASCO (2007) 25:S242 (Abstract). • Another VEGFR inhibitor that is active in renal cancer.
62. KIM S, ROSEN LS, COHEN EE et al.: A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. Proc. ASCO (2006) 24 (Abstract #5529).
63. COHEN EE, VOKES E, ROSEN LS et al.: A Phase II study of axitinib (AG013736[AG]) in patients (pts) with advanced thyroid cancers. Proc. ASCO (2007) 7:S301 (Abstract).
64. WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60(8):2178- 2189.
65. VOGELZANG NJ, STERNBERG CN: Signal-transduction inhibitors in renal cell carcinoma. BJU Int. (2007) 99(5 Part B):1289-1295.
66. LOS M, ROODHART JM, VOEST EE: Target practice: lessons from Phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist (2007) 12(4):443-450.
67. ANTHONY LB, MCCALL J, NUNEZ J, O'DORISIO T, O'DORISIO S: An open-label Phase II clinical trial of PTK787 in patients with progressive neuroendocrine cancer. Proc. ASCO (2007) 25:S621 (Abstract).
68. HUTSON TE, DAVIS ID, MACHIELS JP et al.: Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a Phase II randomized discontinuation trial. Proc. ASCO (2007) 25:S242 (Abstract).
69. FRIEDLANDER M, HANCOCK KC, BENIGNO B et al.: Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancer: initial results of a Phase II study. Proc. ASCO (2007) 25:S289 (Abstract).
70. DREVS J, SIEGERT P, MEDINGER M et al.: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. (2007) 25(20:3045-3054.
71. SRIDHAR SS, HOTTE SJ, MACKENZIE MJ et al.: Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): a trial of the PMH Phase II Consortium. Proc. ASCO (2007) 25:S258 (Abstract).
72. VAN HERPEN C, DREVS J, VAN CRUIJSEN H et al.: Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two Phase I studies. Proc. ASCO (2007) 25:S152 (Abstract).
73. BATCHELOR T, SORENSEN AG, ANCUKIEWICZ M et al.: A Phase II trial of AZD2171(cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Proc. ASCO (2007) 25:S75 (Abstract).
74. GINGRICH DE, REDDY DR, IQBAL MA et al.: A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3- hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. (2003) 46(25):5375-5388.
75. RUGGERI B, SINGH J, GINGRICH D et al.: CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. (2003) 63(18):5978-5991.
76. NAKAMURA K, TAGUCHI E, MIURA T et al.: KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. (2006) 66(18):9134-9142.
77. ESKENS FA, PLANTING A, VAN DOORN L et al.: An open-label Phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growrh factor receptors 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors. Proc. ASCO (2007) 25:S83 (Abstract).
78. ROSEN LS, KURZROCK R, MULAY M et al.: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. (2007) 25(17):2369-2376.
79. POLVERINO A, COXON A, STARNES C et al.: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. (2006) 66(17):8715-8721.
80. SHERMANSI, SCHLUMBERGER MJ, DROZ J et al.: Initial results from a Phase II trial of motesanib diphosphate (AMG-706) in patients with differentiated thyroid cancer (DTC). Proc. ASCO (2007) 25:S303 (Abstract).
81. WIEDMANN M, FEISTHAMMEL J, BLUTHNER T et al.: Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs (2006) 17(7):783-795.
82. TRAXLER P, ALLEGRINI PR, BRANDT R et al.: AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. (2004) 64(14):4931-4941.
83. BHIDE RS, CAI ZW, ZHANG YZ et al.: Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-ol (BMS-54021 5), an in vivo active potent VEGFR-2 inhibitor. J. Med. Chem. (2006) 49(7):2143-2146.
84. KULIMOVA E, OELMANN E, BISPING G et al.: Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol. Cancer Ther. (2006) 5(12):3105-3112.
85. FIEDLER WM, GIACCONE G, LASHCH P et al.: Phase I trial of SU014813 in patients (pts) with advanced solid malignancies. Proc. ASCO (2007) 25:S143 (Abstract).
86. PATYNA S, LAIRD AD, MENDEL DB et al.: SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol. Cancer Ther. (2006) 5(7):1774-1782.
87. HEDBORN S, STEINBILD S, FROST A et al.: Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced tumors. Proc. ASCO (2007) 25:S161(Abstract) .
88. MCCARTHY AA: Exelixis: integrated drug-discovery and development platform for human therapeutics. Chem. Biol. (2005) 12(4):407-408.
89. ARTAVANIS-TSAKONAS S: Accessing the Exelixis collection. Nat. Genet. (2004) 36(3):207.
90. SALGIA R, HONG DS, CAMACHO LH et al.: A Phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies. Proc. ASCO (2007) 25:S614 (Abstract).
91. MARCH RJ, MIRTSCHING B, MODI S, WERTHEIM M: A Phase II study of XL999 in patients (pts) with NSCLC. Proc. ASCO (2007) 25:S692 (Abstract).
92. PORTER LL, BURRIS HA, JONES SF et al.: Summary of results in patients with metastatic renal cell cancer (RCC) from Phase I studies of RAD001(everolimus). Proc. ASCO (2006) 24 (Abstract #14599).
93. JAC J, GIESSINGER S, KHAN M, WILLIS J, CHIANG S, AMATO R: A Phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc. ASCO (2007) 25:S261 (Abstract). • Another potentially active mTOR inhibitor for the treatment of renal cancer.
94. SMOLEWSKI P: Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs (2006) 17(5):487-494.
95. ELIT L: Drug evaluation: AP-23573 - an mTOR inhibitor for the treatment of cancer. Drugs (2006) 9(9):636-644.
96. DESAI A, JANISCH L, BERK LR et al.: A Phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients with refractory or advanced malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Proc. ASCO (2004) 22 (Abstract #3150).
97. CHAWLA SP, TOLCHER AW, STADDON AP et al.: Updated results of a Phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced bone sarcomas. Proc. ASCO (2006) 24 (Abstract #9505).
98. SHAKED Y, KERBEL RS: Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. (2007) 67(15):7055-7058.
99. DHAM A, DUDEK AZ: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Proc. ASCO (2007) 25:S261 (Abstract).
100. SABLIN MP, BOUAITA L, BALLEYGUIER C et al.: Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. Proc. ASCO (2007) 25:S244 (Abstract).
101. GELINAS DS, BERNATCHEZ PN, ROLLIN S, BAZAN NG, SIROIS MG: Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br. J. Pharmacol. (2002) 137(7):1021-1030.
102. KROLL J, WALTENBERGER J: VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2(KDR). Biochem. Biophys. Res. Commun. (1998) 252(3):743-746.
103. SHCHORS K, EVAN G: Tumor angiogenesis: cause or consequence of cancer? Cancer Res. (2007) 67(15):7059-7061.